Mass STI treatment or daily pill? kenya trial tests best way to stop infections

NCT ID NCT06468462

First seen Nov 19, 2025 · Last updated Jun 19, 2026 · Updated 33 times

Summary

This study tests two approaches to prevent sexually transmitted infections (STIs) in cisgender men who have sex with men in Kenya. One group gets a single dose of antibiotics every few months, while another takes doxycycline after sex. The trial will track infections and antibiotic resistance over 18 months to see which strategy works better.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GONORRHEA MALE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Anza Mapema Clinic

    RECRUITING

    Kisumu, Kenya

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • TRANSFORM Clinic

    RECRUITING

    Nairobi, Kenya

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of Washington/Pwani Research Centre at the Ganjoni Municipal Clinic, Mombasa

    RECRUITING

    Mombasa, Kenya

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

cefixime, azithromycin, and doxycycline

What this could lead to

If successful, this could provide effective strategies to control gonorrhea, chlamydia, and syphilis in high-risk populations in resource-limited settings.

What could go wrong

This is a Phase 4 trial, but results may not apply to other populations or settings. Antibiotic resistance is a concern, and the interventions may not reduce infections as hoped.

Conditions

The condition(s) this trial relates to.

chlamydia infectious disease chlamydia trachomatis infectious disease prevention target gonorrhea prevention target syphilis prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.